BrainsWay Announces Prominent Addition to Scientific Advisory Board
12 oct. 2021 09h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay" or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction
30 sept. 2021 08h00 HE
|
BrainsWay
Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:...
BrainsWay to Participate in Two Upcoming Investor Conferences
09 sept. 2021 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
30 août 2021 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients
18 août 2021 07h30 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 18, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders
17 août 2021 07h30 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights
11 août 2021 08h00 HE
|
BrainsWay
Strong Revenue Growth of 45% Year-over-Year in Q2 2021 Gained Meaningful Traction in Reimbursement for Deep TMS™ in both OCD and Depression Conference Call to be held Today at 8:30 AM ET ...
BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021
28 juil. 2021 08h00 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
13 juil. 2021 11h00 HE
|
BrainsWay
Engaging event for local mental health clinicians to learn more about BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in...
BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference
06 juil. 2021 08h00 HE
|
BrainsWay
CRESSKILL, N.J. and JERUSALEM, July 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...